Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
107 hedge funds and large institutions have $4.25B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 35 reducing their positions, and 23 closing their positions.
115% more call options, than puts
Call options by funds: $7.79M | Put options by funds: $3.61M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11% more capital invested
Capital invested by funds: $3.82B → $4.25B (+$428M)
0% more funds holding
Funds holding: 107 → 107 (0)
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
9% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$48.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.9M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$4.96M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$4.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$21.6M |
| 2 |
Goldman Sachs
New York
|
-$9.91M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.53M |
| 4 |
Alkeon Capital Management
New York
|
-$6.18M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.1M |
CERE Hedge Fund Activity: Q1 2022 in Review
107 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q1 2022, worth a combined $4.25B — up 11% from $3.82B a quarter earlier.
Fund positioning in CERE was balanced in Q1 2022: 23 funds opened new positions, 23 closed out, 32 added to existing stakes and 35 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $78.7M. The largest seller was RTW Investments, exiting entirely with an estimated $21.6M sold.
- 107 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $4.25B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q1 2022, up 11% quarter-over-quarter.
- 23 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q1 2022 and 23 closed out, a net change of 0 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q1 2022 was Fidelity Investments, an estimated $78.7M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q1 2022 was RTW Investments, an estimated $21.6M sold.
Based on aggregated 13F filings for Q1 2022.